Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antidepressants for the new millennium.

P Skolnick1

  • 1Neuroscience Discovery, Eli Lilly, Lilly Corporate Center, Indianapolis, IN 46285, USA. skolnick_phil@lilly.com

European Journal of Pharmacology
|August 12, 1999
PubMed
Summary

Novel antidepressants may target N-methyl-D-aspartate (NMDA) receptors, aligning with existing monoamine-based treatments. This research suggests a shared mechanism involving region-specific NMDA receptor function dampening for improved depression treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator.

Proceedings of the National Academy of Sciences of the United States of America·2005
Same author

Modulation of glutamate receptors: strategies for the development of novel antidepressants.

Amino acids·2002
Same author

Ibogaine as a glutamate antagonist: relevance to its putative antiaddictive properties.

The Alkaloids. Chemistry and biology·2001
Same author

Intra- and interstrain differences in models of "behavioral despair".

Pharmacology, biochemistry, and behavior·2001
Same author

AMPA receptor function is altered in GLUR2-deficient mice.

Journal of molecular neuroscience : MN·2001
Same author

[3H]N-2-(4-(N-benzamido)phenyl)propyl-2-propanesulfonamide: a novel AMPA receptor potentiator and radioligand.

Journal of medicinal chemistry·2001

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Conventional antidepressants primarily target monoamine systems (serotonin, norepinephrine, dopamine).
  • Emerging evidence suggests N-methyl-D-aspartate (NMDA) receptor antagonists possess antidepressant properties.
  • Chronic antidepressant use in animal models affects NMDA receptor subunit expression and binding.

Purpose of the Study:

  • To investigate the convergence of monoamine-based and NMDA receptor-targeting antidepressant strategies.
  • To explore the hypothesis that both approaches lead to a common functional endpoint in the central nervous system.
  • To identify potential pathways for novel antidepressant discovery.

Main Methods:

  • Review of preclinical and clinical studies on antidepressant mechanisms.

Related Experiment Videos

  • Analysis of changes in mRNA levels of NMDA receptor subunits following chronic antidepressant administration in mice.
  • Assessment of radioligand binding to NMDA receptors in specific brain regions.

    • Main Results:

    • Both conventional and NMDA-targeting compounds show antidepressant effects.
    • Antidepressant treatments alter NMDA receptor subunit expression and binding in specific CNS areas.
    • A region-specific dampening of NMDA receptor function is proposed as a common functional endpoint.

    Conclusions:

    • Two distinct antidepressant strategies converge on a shared mechanism: reduced NMDA receptor function in specific brain regions.
    • Understanding these convergent pathways offers a framework for developing novel antidepressant medications.
    • Targeting NMDA receptor pathways presents a promising avenue for future depression treatment research.